SCHEMBL4350137

SCHEMBL4350137

CC(O)c1cc(Cl)cc(NC(=S)NC(C)(C)CC(C)(C)C)c1O

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 4/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPT P10636 2/20 0.33
GAA P10253 2/20 0.33
KDM4E B2RXH2 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
LMNA P02545 4/20 0.32
ALOX12 P18054 1/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
SLC2A1 P11166 1/20 0.31
CASR P41180 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4352240 0.86 POLB (0.49) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4345572 0.85 KMT2A (0.41) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4358518 0.83 HTT (0.46) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4343912 0.81 HTT (0.47) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4355998 0.79 GABRA1 (0.41) POLBHTTALDH1A1MAPTGAA
SCHEMBL4350857 0.77 ALDH1A1 (0.47) HTTALDH1A1MEN1KMT2AMAPT
SCHEMBL27761077 0.77 SMN1; SMN2 (0.49) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4346441 0.76 SMN1; SMN2 (0.45) POLBHTTALDH1A1MAPTGAA
SCHEMBL4345664 0.76 POLB (0.49) POLBHTTALDH1A1MEN1KMT2A
SCHEMBL4351070 0.75 SMN1; SMN2 (0.56) POLBHTTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 POLB 3571/4885HTT 3824/4885ALDH1A1 2565/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 POLB 2402/4885HTT 3995/4885ALDH1A1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.